Literature DB >> 9371930

The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial.

.   

Abstract

The objective of our study was to assess the 5-year risk of and prognostic factors for the development of clinically definite multiple sclerosis (CDMS) following optic neuritis. In a prospective cohort study design, 388 patients, who did not have probable or definite MS at study entry enrolled in the Optic Neuritis Treatment Trial between 1988 and 1991, and were followed for the development of CDMS. The 5-year cumulative probability of CDMS was 30% and did not differ by treatment group. Neurologic impairment in the patients who developed CDMS was generally mild. Brain MRI performed at study entry was a strong predictor of CDMS, with the 5-year risk of CDMS ranging from 16% in the 202 patients with no MRI lesions to 51% in the 89 patients with three or more MRI lesions. Independent of brain MRI, the presence of prior nonspecific neurologic symptoms was also predictive of the development of CDMS. Lack of pain, the presence of optic disk swelling, and mild visual acuity loss were features of the optic neuritis associated with a low risk of CDMS among the 189 patients who had no brain MRI lesions and no history of neurologic symptoms or optic neuritis in the fellow eye. The 5-year risk of CDMS following optic neuritis is highly dependent on the number of lesions present on brain MRI. However, even a normal brain MRI does not preclude the development of CDMS. In these patients with no brain MRI lesions, certain clinical features identify a subgroup with a particularly low 5-year risk of CDMS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371930     DOI: 10.1212/wnl.49.5.1404

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  59 in total

Review 1.  Immunologic therapy for relapsing-remitting multiple sclerosis.

Authors:  H J MacLean; M S Freedman
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

Review 2.  Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration.

Authors:  Kristin M Galetta; Peter A Calabresi; Elliot M Frohman; Laura J Balcer
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

3.  Acute Optic Neuritis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-03       Impact factor: 3.598

Review 4.  Early-stage multiple sclerosis : what are the treatment options?

Authors:  Per Soelberg Sorensen
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 5.  Corticosteroids for treating optic neuritis.

Authors:  Robin L Gal; Satyanarayana S Vedula; Roy Beck
Journal:  Cochrane Database Syst Rev       Date:  2015-08-14

Review 6.  Intramuscular interferon-beta-1a: in patients at high risk of developing clinically definite multiple sclerosis.

Authors:  M Asif A Siddiqui; Keri Wellington
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 7.  Corticosteroids for treating optic neuritis.

Authors:  S S Vedula; S Brodney-Folse; R L Gal; R Beck
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

8.  Management of optic neuritis.

Authors:  Vimla Menon; Rohit Saxena; Ruby Misra; Swati Phuljhele
Journal:  Indian J Ophthalmol       Date:  2011 Mar-Apr       Impact factor: 1.848

9.  Independent patterns of damage to retinocortical pathways in multiple sclerosis without a previous episode of optic neuritis.

Authors:  Aldina Reis; Catarina Mateus; M Carmo Macário; José R Faria de Abreu; Miguel Castelo-Branco
Journal:  J Neurol       Date:  2011-03-31       Impact factor: 4.849

10.  Optic Neuritis: A Model for the Immuno-pathogenesis of Central Nervous System Inflammatory Demyelinating Diseases.

Authors:  Gregory F Wu; Chelsea R Parker Harp; Kenneth S Shindler
Journal:  Curr Immunol Rev       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.